Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 1.00 |
| ▸ | PHLPP2 | Q6ZVD8 | 2/20 | 0.80 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.62 |
| ▸ | SENP3 | Q9H4L4 | 6/20 | 0.57 |
| ▸ | SENP2 | Q9HC62 | 6/20 | 0.57 |
| ▸ | SENP1 | Q9P0U3 | 6/20 | 0.57 |
| ▸ | SUMO2 | P61956 | 4/20 | 0.57 |
| ▸ | SUMO1 | P63165 | 4/20 | 0.57 |
| ▸ | SENP7 | Q9BQF6 | 4/20 | 0.57 |
| ▸ | GLO1 | Q04760 | 5/20 | 0.55 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | THRB | P10828 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | APP | P05067 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2541491 | 1.00 | CYP2C9 (1.00) | CYP2C9CYP2C19HSD17B10PHLPP2SLC7A11 | |
| SCHEMBL14418368 | 0.95 | CYP2C9 (0.90) | CYP2C9CYP2C19HSD17B10PHLPP2SLC7A11 | |
| SCHEMBL14413264 | 0.94 | CYP2C9 (0.88) | CYP2C9CYP2C19HSD17B10PHLPP2SLC7A11 | |
| SCHEMBL2585430 | 0.90 | CYP2C9 (0.81) | CYP2C9CYP2C19HSD17B10PHLPP2SLC7A11 | |
| SCHEMBL2585427 | 0.90 | CYP2C9 (0.81) | CYP2C9CYP2C19HSD17B10PHLPP2SLC7A11 | |
| SCHEMBL12224760 | 0.89 | PHLPP2 (1.00) | CYP2C9CYP2C19HSD17B10PHLPP2SLC7A11 | |
| SCHEMBL12177913 | 0.89 | CYP2C9 (0.79) | CYP2C9CYP2C19HSD17B10PHLPP2SLC7A11 | |
| SCHEMBL12177898 | 0.86 | CYP2C9 (0.76) | CYP2C9CYP2C19HSD17B10PHLPP2SLC7A11 | |
| SCHEMBL12177917 | 0.86 | CYP2C9 (0.75) | CYP2C9CYP2C19HSD17B10PHLPP2SLC7A11 | |
| SCHEMBL2587653 | 0.85 | CYP2C9 (0.73) | CYP2C9CYP2C19HSD17B10PHLPP2SLC7A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7264932-B2 | Nuclease inhibitor cocktail | APPLERA CORPORATION (US) | 2007-09-04 | — | — | US | claimed |
| WO-2005083081-A1 | IMPROVED NUCLEASE INHIBITOR COCKTAIL | AMBION, INC. (US) | 2005-09-09 | — | — | WO | claimed |
| US-20050014169-A1 | Nuclease inhibitor cocktail | AMBION, INC. | 2005-01-20 | — | — | US | claimed |
| US-20250163502-A1 | METHODS FOR PROCESSING RIBONUCLEIC ACIDS IN BIOLOGICAL SAMPLES | 10X GENOMICS, INC. | 2025-05-22 | — | — | US | disclosed |
| US-20240376521-A1 | BORONIC ACID COMPOSITIONS AND METHODS FOR TETHERING RIBONUCLEIC ACIDS IN BIOLOGICAL SAMPLES | 10X GENOMICS, INC. | 2024-11-14 | — | — | US | disclosed |
| EP-4461816-A1 | BORONIC ACID COMPOSITIONS AND METHODS FOR TETHERING RIBONUCLEIC ACIDS IN BIOLOGICAL SAMPLES | 10X Genomics, Inc. (US) | 2024-11-13 | — | — | EP | disclosed |
| US-20240218424-A1 | METHODS FOR TETHERING RIBONUCLEIC ACIDS IN BIOLOGICAL SAMPLES | 10X GENOMICS, INC. | 2024-07-04 | — | — | US | disclosed |
| WO-2024137860-A1 | METHODS FOR TETHERING RIBONUCLEIC ACIDS IN BIOLOGICAL SAMPLES | 10X GENOMICS, INC. (US) | 2024-06-27 | — | — | WO | disclosed |
| US-20240167107-A1 | COMPOSITION AND METHOD FOR NUCLEIC ACID DETECTION | APTITUDE MEDICAL SYSTEMS, INC. (US) | 2024-05-23 | — | — | US | disclosed |
| WO-2022177842-A1 | COMPOSITION AND METHOD FOR NUCLEIC ACID DETECTION | APTITUDE MEDICAL SYSTEMS, INC (US) | 2022-08-25 | — | — | WO | disclosed |
| US-20210223230-A1 | Neamine Compositions and Methods of Use Thereof | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2021-07-22 | — | — | US | disclosed |
| US-7264932-B2 | Nuclease inhibitor cocktail | APPLERA CORPORATION (US) | 2007-09-04 | — | — | US | disclosed |
| US-7264932-B2 | Nuclease inhibitor cocktail | APPLERA CORPORATION (US) | 2007-09-04 | — | — | US | disclosed |
| US-7264932-B2 | Nuclease inhibitor cocktail | APPLERA CORPORATION (US) | 2007-09-04 | — | — | US | disclosed |
| US-20070032418-A1 | Small-molecule inhibitors of angiogenin and rnases and in vivo and in vitro methods of using same | AMBION, INC (US) | 2007-02-08 | — | — | US | disclosed |
| US-20070032418-A1 | Small-molecule inhibitors of angiogenin and rnases and in vivo and in vitro methods of using same | AMBION, INC (US) | 2007-02-08 | — | — | US | disclosed |
| US-20070032418-A1 | Small-molecule inhibitors of angiogenin and rnases and in vivo and in vitro methods of using same | AMBION, INC (US) | 2007-02-08 | — | — | US | disclosed |
| WO-2005083081-A1 | IMPROVED NUCLEASE INHIBITOR COCKTAIL | AMBION, INC. (US) | 2005-09-09 | — | — | WO | disclosed |
| US-20050014169-A1 | Nuclease inhibitor cocktail | AMBION, INC. | 2005-01-20 | — | — | US | disclosed |
| WO-2004076640-A2 | SMALL-MOLECULE INHIBITORS OF ANGIOGENIN AND RNASES AND IN VIVO AND IN VITRO METHODS OF USING SAME | AMBION, INC. (US) | 2004-09-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032418-A1 | Small-molecule inhibitors of angiogenin and rnases and in vivo and in vitro methods of using same | RNASE1, RNASEH1, RNASEL | CYP2C9 4801/4885CYP2C19 4749/4885HSD17B10 2691/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.